Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis

4th Edition

Product Code KAL00140
Publication Date September 2010
Publisher Kalorama Information
Product Type Report
Pages 65535
ISBN Number not applicable
Change currency
PDF £2,525.00 €3,041 $3,993 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis

4th Edition

Kalorama has been researching and examining the development of cancer vaccines for seven years. In April 2010, the cancer vaccine market experienced one of the largest achievements for therapeutic vaccine treatment of cancer-the approval of prostate cancer vaccine PROVENGE (TM). This, in addition to the success of cervical cancer vaccine products, has created a viable market for what was a decade a go merely a speculative area.

Even with achievements for some companies, numerous vaccines with apparently strong prospects have been hit by developmental delays and failures. These include CancerVax's Canvaxin, Aphton's Insegia, Progenics' GMK vaccine, and Biomira's Theratope. Despite setbacks many developers are hopeful of a turnaround. With a couple prophylactic vaccines for cervical cancer on the market, a few select therapeutic vaccine approvals and several therapeutic vaccines on a promising path to commercialization, the market could see a surge of regulatory activity and an influx of market opportunities.

This Kalorama Information report - New Developments in the Cancer Vaccine Market, 2010 - focuses on both preventive and therapeutic cancer vaccines in development. Cancers with vaccine development or potential are profiled in this report, some of these include:

  • Cervical
  • Colon/Rectal
  • Lung
  • Lymphoma
  • Melanoma
  • Prostate
  • Breast
  • Gastrointestinal
  • Renal
  • Brain
  • Bladder
  • Ovarian
  • Leukemia

The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there is current vaccines development are profiled. Each market segment provides an overview, descriptions of products available or in development, market estimates and forecasts for 2010-2015, and competitive analysis of leading developers for 2015. The report also includes current issues and trends affecting the industry.

This area of medicine is a new frontier and many of the issues that face the cancer vaccine market are novel. However, this is a very promising area of medicine, which will continue to assist in the fight against cancer.

Issues and trends discussed in The Emerging Cancer Vaccine Market include:

  • Early Detection and Screening
  • Monoclonal Antibodies and Therapeutic Vaccines
  • Safety Concerns
  • Insurance and Reimbursement Issues
  • Personalized Medicine
  • Pharmacogenomics
  • Vaccine Strategies
  • Economic Conditions and Vaccine Discovery

Contents

  • Chapter One: Executive Summary
    • Introduction
    • Disease Burden
    • Scope and Methodology
    • Size and Growth of The Market
    • Issues and Trends Affecting Market
    • Leading Competitors
  • Chapter Two: Introduction
    • Introduction
    • Cancer Descriptions
    • Timeline of Cancer Vaccine Developments
    • History and Growth of The Cancer Treatment Market
    • Types of Vaccines
    • Antigen/Adjuvant Vaccines
    • Whole Cell Tumor Vaccines
    • Dendritic Cell (Dc) Vaccines
    • Viral Vectors and DNA Vaccines
    • Idiotype Vaccines
    • Types of Therapeutic Vaccines
    • Patient-Specific Vaccines
    • Prostate Specific Antigen
    • Sialyl Tn
    • Heat Shock Proteins
    • Ganglioside Molecules
    • Carcinoembryonic Antigen (Cea)
    • Mart-1
    • Tyrosinase
    • Adjuvants
    • Industry Structure
    • Demographics and Statistics
    • Growing and Aging Population
    • Tobacco Use and Obesity Increases Cancer Risk
    • Tobacco Use
    • Obesity
    • Life Expectancy and Cancer
  • Chapter Three: Cervical Cancer Vaccines
    • Overview
    • Description of Vaccines on The Market
    • Gardasil/Silgard
    • Cervarix
    • Description of Vaccines in Development
    • V503
    • Rg3484
    • Pv701
    • Lovaxin C
    • Vgx-3100
    • Ca-9
    • Market Summary
    • Current and Potential Competitors and Analysis, 2015
  • Chapter Four: Colon/Rectal Cancer Vaccines
    • Overview
    • Description of Vaccines on The Market
    • Oncovax
    • Description of Vaccines in Development
    • Oncovax
    • Trovax
    • Cea Vrp Vaccine (Avx701)
    • Ima910
    • Cdx-1307
    • Tumor Associated Antigen Therapeutic Vaccine - Cea DNA Cancer Vaccine
    • Mkc1106-Pp
    • Gi-4000
    • Gvax
    • Oncophage
    • Crs-207
    • Lapuleucel-T
    • Market Summary
    • Potential Competitors and Analysis, 2015
  • Chapter Five: Lung Cancer Vaccines
    • Overview
    • Description of Vaccines in Development
    • Lucanix
    • Mage-A3 Peptide
    • Stimuvax
    • Egf Cancer Vaccine
    • Hyperacute Lung
    • Gi-4000
    • Oncophage
    • Tg 4010
    • Lungvax
    • Tumor Associated Antigen Therapeutic Vaccine - Cea DNA Cancer Vaccine
    • Dcvax-Lung
    • Market Summary
    • Potential Competitors and Analysis, 2015
  • Chapter Six: Lymphoma Vaccines
    • Overview
    • Description of Vaccines in Development
    • Biovaxid
    • Myvax
    • Market Summary
    • Potential Competitors and Analysis, 2015
  • Chapter Seven: Melanoma Vaccines
    • Overview
    • Description of Vaccines on The Market
    • Description of Vaccines in Development
    • Mvax
    • Allovectin-7
    • Mdx-1379 with Combination Treatment Mdx-010
    • Oncophage
    • Mage-A3 Asci
    • Alvac Vaccine
    • Hyperacute Melanoma
    • Market Summary
    • Potential Competitors and Analysis, 2015
  • Chapter Eight: Prostate Cancer Vaccines
    • Overview
    • Description of Vaccines on The Market
    • Provenge
    • Description of Vaccines in Development
    • Dcvax-Prostate
    • Gvax
    • Prostvac-Vf
    • Trovax
    • Onyvax-P
    • Mva-Bn Prostate
    • Hyperacute Prostate
    • Neuvax
    • Mkc1106-Pp
    • Market Summary
    • Potential Competitors and Analysis, 2015
  • Chapter Nine: Breast Cancer Vaccines
    • Overview
    • Description of Vaccines in Development
    • Stimuvax
    • Neuvax
    • Gvax
    • Avx701 Vaccine
    • Mva-Bn Her2
    • Lapuleucel-T
    • Cdx-1307-02
    • Tumor Associated Antigen Therapeutic Vaccine - Cea DNA Cancer Vaccine
    • Mkc1106-Pp
    • Market Summary
  • Chapter Ten: Gastrointestinal Cancer Vaccines
    • Overview
    • Description of Vaccines in Development
    • Gi-4000
    • Hyperacute Pancreas
    • Gvax
    • Oncophage
    • Cdx-1307
    • Anz-100
    • Dcvax
    • Market Summary
  • Chapter Eleven: Renal Cancer Vaccines
    • Overview
    • Description of Vaccines on The Market
    • Oncophage
    • Description of Vaccines in Development
    • Oncophage
    • Reniale
    • Trovax
    • Ima901
    • Ags-003
    • Mdx-1106
    • Mkc1106-Pp
    • Market Summary
    • Potential Competitors and Analysis, 2015
  • Chapter Twelve: Brain Cancer Vaccines
    • Overview
    • Glioblastoma
    • Neuroblastoma
    • Description of Vaccines in Development
    • Dcvax-Brain
    • Cdx-110
    • Gliaatak
    • Oncophage
    • Market Summary
  • Chapter Thirteen: Bladder Cancer Vaccines
    • Overview
    • Description of Vaccines on The Market
    • Bcg Therapy (Oncotice- Organon Teknika) (Immucyst-Sanofi Pasteur)(Pacis-
    • Shire Pharmaceuticals)
    • Description of Vaccines in Development
    • Cdx-1307
    • Market Summary
  • Chapter Fourteen: Ovarian Cancer Vaccines
    • Overview
    • Description of Vaccines in Development
    • Abagovomab
    • Ovax Autologous Cell Vaccine
    • Lapuleucel-T
    • Tumor Associated Antigen Therapeutic Vaccine - Cea DNA Cancer Vaccine
    • Mkc1106-Pp
    • Market Summary
  • Chapter Fifteen: Leukemia Vaccines
    • Overview
    • Description of Vaccines in Development
    • Gvax-Leukemia
    • Grnvac1
    • Pr1 Peptide Vaccine
    • Market Summary
  • Chapter Sixteen: Issues and Trends Affecting The Cancer Vaccine Market
    • Introduction
    • Early Detection and Screening
    • Monoclonal Antibodies and Therapeutic Vaccines
    • Political and Social Pressure
    • Safety Concerns
    • Insurance and Reimbursement Issues
    • Personalized Medicine
    • Pharmacogenomics
    • Vaccine Strategies
    • Economic Conditions Affect Investing in Some Cancer Vaccine Discovery
  • Chapter Seventeen The Cancer Vaccine Market: Market Forecasts
    • Overview
    • Total Market Size and Forecast
    • Prophylactic Versus Therapeutic Cancer Vaccine Market Size
    • Market and Competitor Analysis
  • Chapter Eighteen Cancer Vaccine Corporate Profiles
    • Introduction
    • Accentia Biopharmaceuticals, Inc.
    • Antigenics, Inc.
    • Avax Technologies, Inc.
    • Dendreon Corporation
    • Glaxosmithkline Plc
    • Merck & Company, Inc.
    • Northwest Biotherapeutics, Inc.
    • Oncothyreon, Inc
    • Vaccinogen, Inc.
    • Appendix: Company Names and Addresses
    • List of Exhibits
  • Chapter One: Executive Summary
    • Table 1-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
    • Figure 1-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
    • Figure 1-2 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2015
  • Chapter Two: Introduction
    • Table 2- Significant Cancer Vaccine Approvals, 2000-201
    • Table 2-2 World Cancer Incidence by Selected Types of Cancer, 2010 and 2020, All Races, Both Sexe
    • Figure 2-1 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020
    • Table 2-3 Total Cancer Incidence by Sex and Country, 2010 Estimates
    • Figure 2-2 Total Cancer Incidence by Sex and Country, 2010 Estimates
    • Table 2-4 World Population by Selected Geographical Region, 2010 - 2050
    • Figure 2-3 World Population by Selected Geographical Region, 2010-2050
    • Table 2-5 Percent Population over 65 by Year and Region, 2010-2050
    • Figure 2-4 Estimated World Population by Age, 2010 and 2050
    • Table 2-6 Percent of Smokers by Country
    • Figure 2-5 Average Percent of Smokers Worldwide in Developed Regions
    • Table 2-7 Estimated Obesity by Country 2009 Estimates
    • Figure 2-6 Estimated Obesity by Country as A Portion of Total Population 2009 Estimates
    • Figure 2-7 Increases in Obesity by Country-2007 and 2009 Figures
    • Table 2-8 Life Expectancy at Birth by Selected Countries, 2006
    • Figure 2-8 United States Average Years of Life Lost per Person Dying of Cancer, All Races, Both Sexes, 2006
    • Figure 2-9 United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2006
    • Figure 2-10 United States Person-Years of Life Lost Due to Major Causes of Death, All Races, Both Sexes, 2006
  • Chapter Three: Cervical Cancer Vaccines
    • Table 3-1 Estimated World Incidence of Cervical Cancer by Country, 2010
    • Figure 3-1 Estimated World Incidence of Cervical Cancer by Country, 2010
    • Table 3-2 Cervical Cancer Vaccines Approved and in The Pipeline
    • Table 3-3 The Developing Cervical Cancer Vaccine Market, 2007-2015
    • Figure 3-2 The Developing Cervical Cancer Vaccine Market, 2007-2015
    • Table 3-4 The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
    • Figure 3-3 The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
    • Figure 3-4 Product Sales by Year for Cervical Cancer Vaccines, 2007-2015
  • Chapter Four: Colon/Rectal Cancer Vaccines
    • Table 4-1 Estimated World Incidence of Colon/Rectal Cancer by Country, 2010
    • Figure 4-1 Estimated World Incidence of Colon/Rectal Cancer by Country, 2010
    • Table 4-2 Colon/Rectal Cancer Vaccines in The Pipeline
  • Chapter Five: Lung Cancer Vaccines
    • Table 5-1 Types of Primary Lung Cancer
    • Table 5-2 Estimated World Incidence of Lung Cancer by Country, 2010
    • Figure 5-1 Estimated World Incidence of Lung Cancer by Country, 2010
    • Table 5-3 Lung Cancer Vaccines in The Pipeline
  • Chapter Six: Lymphoma Vaccines
    • Table 6-1 Classification of Non-Hodgkin's Lymphomas
    • Table 6-2 Estimated World Incidence of Lymphoma by Country, 2010
    • Figure 6-1 Estimated World Incidence of Lymphoma by Country, 2010
    • Table 6-3 Lymphoma Vaccines in The Pipeline
  • Chapter Seven: Melanoma Vaccines
    • Table 7-1 Malignant Conditions of The Skin
    • Table 7-2 Estimated World Incidence of Melanoma by Country, 2010
    • Figure 7-1 Estimated World Incidence of Melanoma by Country, 2010
    • Table 7-3 Melanoma Vaccines in The Pipeline
    • Table 7-3 (Continued) Melanoma Vaccines in The Pipeline
    • Table 7-4 The Developing Melanoma Vaccine Market, 2007-2015
    • Figure 7-2 The Developing Melanoma Vaccine Market, 2007-2015
    • Table 7-5 The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
    • Figure 7-3 The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
    • Figure 7-4 Product Sales by Year for Developing Melanoma Vaccines, 2007-2015
  • Chapter Eight: Prostate Cancer Vaccines
    • Table 8-1 Estimated World Incidence of Prostate Cancer by Country, 2010
    • Figure 8-1 Estimated World Incidence of Prostate Cancer by Country, 2010
    • Table 8-2 Prostate Cancer Vaccines in The Pipeline
    • Table 8-2 (Continued) Prostate Cancer Vaccines in The Pipeline
    • Table 8-3 The Emerging Prostate Cancer Vaccine Market, 2010-2015
    • Figure 8-2 The Emerging Prostate Cancer Vaccine Market, 2010-2015
    • Table 8-4 The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
    • Figure 8-3 The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
    • Figure 8-4 Anticipated Product Sales by Year for Emerging Prostate Vaccines, 2010-2015
  • Chapter Nine: Breast Cancer Vaccines
    • Table 9-1 Estimated World Incidence of Breast Cancer by Country, 2010
    • Figure 9-1 Estimated World Incidence of Breast Cancer by Country, 2010
    • Table 9-2 Breast Cancer Vaccines in The Pipeline
  • Chapter Ten: Gastrointestinal Cancer Vaccines
    • Table 10-1 Estimated World Incidence of Gastrointestinal Cancer by Country, 2010
    • Figure 10-1 Estimated World Incidence of Gastrointestinal Cancer by Country, 2010
    • Table 10-2 Gastrointestinal Cancer Vaccines in The Pipeline
  • Chapter Eleven: Renal Cancer Vaccines
    • Table 11-1 Estimated World Incidence of Renal Cancer by Country, 2010
    • Figure 11-1 Estimated World Incidence of Renal Cancer by Country, 2010
    • Table 11-2 Renal Cancer Vaccines in The Pipeline
  • Chapter Twelve: Brain Cancer Vaccines
    • Table 12-1 Estimated World Incidence of Brain Cancer by Country, 2010
    • Figure 12-1 Estimated World Incidence of Brain Cancer by Country, 2010
    • Table 12-2 Brain Cancer Vaccines in The Pipeline
  • Chapter Thirteen: Bladder Cancer Vaccines
    • Table 13-1 Estimated World Incidence of Bladder Cancer by Country, 2010
    • Figure 13-1 Estimated World Incidence of Bladder Cancer by Country, 2010
    • Table 13-2 Bladder Cancer Vaccines in The Pipeline
  • Chapter Fourteen: Ovarian Cancer Vaccines
    • Table 14-1 Estimated World Incidence of Ovarian Cancer by Country, 2010
    • Figure 14-1 Estimated World Incidence of Ovarian Cancer by Country, 2010
    • Table 14-2 Ovarian Cancer Vaccines in The Pipeline
  • Chapter Fifteen: Leukemia Vaccines
    • Table 15-1 Types of Leukemia
    • Table 15-2 Estimated World Incidence of Leukemia by Country, 2010
    • Figure 15-1 Estimated World Incidence of Leukemia Cancer by Country, 2010
    • Table 15-3 Leukemia Vaccines in The Pipeline
  • Chapter Sixteen: Issues and Trends Affecting The Cancer Vaccine Market
    • Table 16-1 Cancer Detection Tests
    • Table 16-2 Early Safety Statistics Concerning Hpv Vaccination
  • Chapter Seventeen: The Cancer Vaccine Market: Market Forecasts
    • Table 17-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
    • Figure 17-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
    • Figure 17-2 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2015
    • Figure 17-3 Cancer Vaccines: Prophylactic and Therapeutic Cancer Vaccine Markets, 2007-2015 208
    • Figure 17-2 Cancer Vaccines: Prophylactic and Therapeutic Cancer Vaccine Markets by Percent, 2015
    • Cancer Vaccine Corporate Profile: Company Names and Addresses